Glenmark Life Sciences, 543322, GLS Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

10,123.19
19.49
2

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

9,680.12
2.54%
4.03

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

-
19.51
4.66

EBITDA CAGR (%)

10 Years
5 Years
3 Years

-
21.05
1.68

PAT CAGR (%)

10 Years
5 Years
3 Years

-
19.01
9.92

P:E (Median)

8 Years
5 Years
3 Years

-
-
15.40

P:BV (Average)

8 Years
5 Years
3 Years

-
-
3.09

EV:EBITDA (Average)

8 Years
5 Years
3 Years

-
-
10.12

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated

Description Dec 23 Dec 22 Var% Sep 23 Sep 22 Var% Jun 23 Jun 22 Var% Mar 23 Mar 22 Var%
Net Sales 572.80 540.73 5.93% 595.36 509.30 16.90% 578.45 489.87 18.08% 621.32 514.06 20.87%
Expenses 400.25 395.27 1.26% 428.28 365.66 17.13% 385.29 343.10 12.30% 414.89 371.85 11.57%
EBITDA 172.56 145.46 18.63% 167.08 143.64 16.32% 193.16 146.77 31.61% 206.43 142.21 45.16%
EBIDTM 30.12% 26.90% 28.06% 28.20% 33.39% 29.96% 33.22% 27.66%
Other Income 1.69 6.61 -74.43% 5.37 10.02 -46.41% 1.85 9.49 -80.51% 2.84 5.10 -44.31%
Interest 0.39 0.16 143.75% 0.40 0.13 207.69% 0.40 0.14 185.71% 0.12 0.13 -7.69%
Depreciation 13.18 10.76 22.49% 13.13 9.93 32.23% 12.61 9.88 27.63% 11.52 9.55 20.63%
PBT 160.68 141.14 13.84% 158.93 143.59 10.68% 182.00 146.25 24.44% 197.63 137.63 43.60%
Tax 41.92 36.15 15.96% 40.19 36.71 9.48% 46.55 37.51 24.10% 51.27 38.73 32.38%
PAT 118.77 104.99 13.13% 118.74 106.88 11.10% 135.45 108.73 24.57% 146.36 98.90 47.99%
PATM 20.73% 19.42% 19.94% 20.99% 23.42% 22.20% 23.56% 19.24%
EPS 9.70 8.57 13.19% 9.69 8.72 11.12% 11.06 8.88 24.55% 11.95 8.07 48.08%

Description Dec 23 Dec 22 Var% Sep 23 Sep 22 Var% Jun 23 Jun 22 Var% Mar 23 Mar 22 Var%
Net Sales 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Expenses 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
EBITDA 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
EBIDTM 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Other Income 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Interest 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Depreciation 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PBT 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Tax 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PAT 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PATM 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0

Annual Results

Standalone Figures in Rs. Crores

Description TTM Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18
Net Sales 2,367.93 2,161.22 2,123.21 1,885.16 1,537.31 886.42 0.25 Net Sales Growth 15.29% 1.79% 12.63% 22.63% 73.43% 354468.00% Cost Of Goods Sold 1,043.68 984.12 1,019.28 877.46 664.02 331.97 0.05 Gross Profit 1,324.25 1,177.10 1,103.93 1,007.70 873.29 554.45 0.20 GP Margin 55.92% 54.46% 51.99% 53.45% 56.81% 62.55% 80.0% Total Expenditure 1,628.71 1,518.93 1,507.15 1,294.09 1,065.35 639.25 0.26 Power & Fuel Cost - 115.60 100.92 74.19 76.75 57.81 0.00 % Of Sales - 5.35% 4.75% 3.94% 4.99% 6.52% 0% Employee Cost - 180.18 168.72 149.13 142.28 106.28 0.15 % Of Sales - 8.34% 7.95% 7.91% 9.26% 11.99% 60.0% Manufacturing Exp. - 137.17 124.04 107.61 108.03 77.23 0.04 % Of Sales - 6.35% 5.84% 5.71% 7.03% 8.71% 16.00% General & Admin Exp. - 46.45 54.18 43.36 44.09 29.51 0.02 % Of Sales - 2.15% 2.55% 2.30% 2.87% 3.33% 8.00% Selling & Distn. Exp. - 45.10 31.78 33.79 26.32 27.91 0.00 % Of Sales - 2.09% 1.50% 1.79% 1.71% 3.15% 0% Miscellaneous Exp. - 10.30 8.23 8.54 3.86 8.53 0.00 % Of Sales - 0.48% 0.39% 0.45% 0.25% 0.96% 0% EBITDA 739.23 642.29 616.06 591.07 471.96 247.17 -0.01 EBITDA Margin 31.22% 29.72% 29.02% 31.35% 30.70% 27.88% -4.00% Other Income 11.75 28.96 14.70 0.81 11.99 0.99 0.00 Interest 1.31 0.55 27.96 87.55 33.52 0.61 0.00 Depreciation 50.44 42.09 37.88 33.39 29.37 19.26 0.00 PBT 699.24 628.61 564.92 470.94 421.07 228.30 -0.01 Tax 179.93 161.65 146.20 119.36 107.97 32.70 0.42 Tax Rate 25.73% 25.72% 25.88% 25.35% 25.64% 14.32% -4200.00% PAT 519.32 466.96 418.72 351.58 313.10 195.59 -0.43 PAT before Minority Interest 519.32 466.96 418.72 351.58 313.10 195.59 -0.43 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 21.93% 21.61% 19.72% 18.65% 20.37% 22.07% -172.00% PAT Growth 23.79% 11.52% 19.10% 12.29% 60.08% - EPS 42.39 38.12 34.18 28.70 25.56 15.97 -0.04

Results Balance Sheet

Standalone Figures in Rs. Crores

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18
Shareholder's Funds 2,138.21 2,054.31 752.75 401.69 88.13 -1.40 Share Capital 24.50 24.50 1.96 1.96 1.96 0.01 Total Reserves 2,107.02 2,026.31 750.79 399.73 86.17 -1.41 Non-Current Liabilities 59.53 32.70 22.89 16.45 6.86 0.00 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 0.00 0.00 0.00 0.00 0.00 0.00 Current Liabilities 1,022.76 746.80 1,444.93 1,307.46 1,380.41 1.48 Trade Payables 396.56 307.72 221.31 201.07 182.89 0.01 Other Current Liabilities 85.24 49.84 966.54 1,084.03 1,181.11 1.46 Short Term Borrowings 0.00 0.00 0.00 0.02 0.02 0.00 Short Term Provisions 540.96 389.24 257.08 22.34 16.40 0.01 Total Liabilities 3,220.50 2,833.81 2,220.57 1,725.60 1,475.40 0.08 Net Block 780.63 589.76 572.80 546.25 456.31 0.00 Gross Block 936.48 705.53 651.90 594.82 475.57 0.00 Accumulated Depreciation 155.85 115.77 79.10 48.58 19.26 0.00 Non Current Assets 851.81 706.42 598.03 565.49 544.70 0.00 Capital Work in Progress 61.62 96.95 14.10 10.73 80.39 0.00 Non Current Investment 0.08 0.08 0.08 0.08 0.08 0.00 Long Term Loans & Adv. 9.49 19.63 11.06 8.44 7.92 0.00 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 Current Assets 2,368.68 2,127.39 1,622.53 1,160.11 930.70 0.08 Current Investments 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 604.17 516.24 513.42 412.77 400.84 0.04 Sundry Debtors 806.77 673.49 619.50 638.63 448.09 0.03 Cash & Bank 309.40 512.16 115.60 10.00 2.06 0.01 Other Current Assets 648.35 5.96 70.31 33.71 79.70 0.01 Short Term Loans & Adv. 577.27 419.54 303.70 65.00 18.04 0.01 Net Current Assets 1,345.92 1,380.59 177.60 -147.35 -449.72 -1.40 Total Assets 3,220.49 2,833.81 2,220.56 1,725.60 1,475.40 0.08

Cash Flow

Standalone Figures in Rs. Crores

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18
Cash From Operating Activity 313.40 597.59 388.11 195.01 10.35 -0.48 PBT 628.61 564.92 470.94 421.07 228.30 -0.01 Adjustment 35.32 70.99 133.31 56.74 -101.15 0.00 Changes in Working Capital -196.96 99.84 -107.58 -190.26 -93.26 -0.47 Cash after chg. in Working capital 466.97 735.75 496.68 287.54 33.89 -0.48 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -153.56 -138.17 -108.56 -92.54 -23.54 0.00 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -154.15 -122.23 -68.73 -50.52 -8.91 0.00 Net Fixed Assets -195.62 -136.48 -60.45 -49.59 -555.96 Net Investments 0.00 0.00 0.00 0.00 -0.08 Others 41.47 14.25 -8.28 -0.93 547.13 Cash from Financing Activity -387.59 -78.80 -213.78 -136.55 0.54 0.49 Net Cash Inflow / Outflow -228.33 396.56 105.60 7.94 1.97 0.01 Opening Cash & Equivalents 512.16 115.60 10.00 2.06 0.01 0.00 Closing Cash & Equivalent 283.82 512.16 115.60 10.00 2.06 0.01

Financial Ratios

Standalone

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18
Book Value (Rs.) 173.97 167.38 69.83 37.26 449.62 -1398.00 ROA 15.43% 16.57% 17.82% 19.56% 26.51% -510.59% ROE 22.33% 29.87% 60.91% 127.84% 451.05% 0.00% ROCE 30.01% 42.24% 96.75% 185.60% 527.74% 0.00% Fixed Asset Turnover 2.65 3.13 3.03 2.88 3.73 248.00 Receivable days 124.34 111.01 121.50 128.84 92.26 45.63 Inventory Days 94.11 88.40 89.45 96.46 82.54 55.93 Payable days 130.60 94.72 87.85 65.75 52.18 24.84 Cash Conversion Cycle 87.84 104.69 123.10 159.54 122.62 76.71 Total Debt/Equity 0.00 0.00 0.00 0.00 0.00 0.00 Interest Cover 1150.19 21.20 6.38 13.56 378.35 0.00

Top Investors:

massachusetts institute of technology

Annual Reports:

News Update:

Nirma acquires majority stake in Glenmark Life Sciences
13th Mar 2024, 12:09 PM

This strategic acquisition marks a significant milestone for Nirma as it strengthens its presence in the pharmaceuticals and life sciences sector
Read More
Glenmark Life Scienc - Quarterly Results
23rd Jan 2024, 17:20 PM

Read More
Glenmark Life Sciences inks pact with Japanese innovator pharmaceutical company
19th Jan 2024, 10:40 AM

The company will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Read More

Glenmark Life Sciences Ltd.

Pharmaceuticals & Drugs

BSE: 543322 | NSE: GLS

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Standalone Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

Top Investors:

Annual Reports:

News Update:

Glenmark Life Sciences Ltd.

Pharmaceuticals & Drugs

BSE: 543322 | NSE: GLS

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Standalone Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

Top Investors:

Annual Reports:

News Update: